Geen categorie

ROTTERDAM, The Netherlands, January 11, 2021 – The partnership between the young company Pan Cancer T B.V. and Erasmus MC is awarded a Health~Holland grant of […]

– Strengthening of T cell research expertise to develop next-generation T cell therapies for patients with limited or no treatment options  ROTTERDAM, January 17, 2023 – […]

– Leading European T cell therapy researcher adds further scientific expertise   ROTTERDAM, February 23, 2023 – Pan Cancer T B.V., a biotech spin-off from Erasmus […]

ROTTERDAM, May 11, 2023 – Pan Cancer T B.V., a biotech spin-off from Erasmus MC dedicated to the discovery and development of next-generation TCR-T therapies against […]

– John Tchelingerian, PhD (Chair), Dharminder Singh Chahal and Prof. Dr. Chris Bangma to form Supervisory Board ROTTERDAM, March 30, 2021 – Pan Cancer T B.V., […]

Pan Cancer T B-day_2021 (2)

Expanded investor syndicate strengthens the company’s financial position and investor base   ROTTERDAM, October 28, 2021 – Pan Cancer T B.V., a biotech spin-off from the […]

Pan Cancer T is awarded with Axon Innovation for Health Award 2021 – selected as the winner out of 21 start-up companies Hilversum, 15 April 2021 […]

Life-saving TCR T-cell therapies for hard-to-treat solid tumors – Dutch biotech company developing first-in-class T-cell Receptor (TCR) T-cell therapies – Seed investment by Swanbridge Capital and […]